Hereditary Kidney Cancer Syndromes

Advances in Chronic Kidney Disease

Volumn 21, Issue 1, 2014, Pages 81-90

  Haas, Naomi B ^a   Nathanson, Katherine L ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Birt Hogg Dube disease; Genetic disease; Genetic susceptibility; Kidney cancer; Von Hippel Lindau disease

Indexed keywords

FUMARATE HYDRATASE; SUCCINATE DEHYDROGENASE;

ANGIOMYOLIPOMA; BIRT HOGG DUBE SYNDROME; CANCER RISK; CHROMOSOME 3; CLINICAL RESEARCH; COWDEN SYNDROME; FAMILIAL CANCER; GENE MUTATION; HAMARTOMA; HUMAN; KIDNEY CANCER; KIDNEY CELL; LEIOMYOMATOSIS; PRIORITY JOURNAL; REVIEW; TUBEROUS SCLEROSIS; VON HIPPEL LINDAU DISEASE;

BIRT-HOGG-DUBE DISEASE; GENETIC DISEASE; GENETIC SUSCEPTIBILITY; KIDNEY CANCER; VON HIPPEL LINDAU DISEASE;

BIRT-HOGG-DUBE SYNDROME; CARCINOMA, RENAL CELL; CHROMOSOMES, HUMAN, PAIR 3; GENETIC PREDISPOSITION TO DISEASE; HAMARTOMA SYNDROME, MULTIPLE; HUMANS; KIDNEY NEOPLASMS; LEIOMYOMATOSIS; NEOPLASTIC SYNDROMES, HEREDITARY; PROTO-ONCOGENE PROTEINS C-MET; SKIN NEOPLASMS; SUCCINATE DEHYDROGENASE; TRANSLOCATION, GENETIC; TUBEROUS SCLEROSIS; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN THIOLESTERASE; UTERINE NEOPLASMS; VON HIPPEL-LINDAU DISEASE;

EID: 84890606276     PISSN: 15485595     EISSN: 15485609     Source Type: Journal    
DOI: 10.1053/j.ackd.2013.10.001     Document Type: Review

References (127)

1. Von Hippel E. Uber eine sehr seltene Erkanung der netzhaut. Graefes Arch Clin Exp Opthalmol 1904, 59(1):83-106. (German).
2. Lindau A. Studien ber kleinbirncysten bau: pathogenese und beziehungen zur angiomatosis retinae. Acta Radiol Microbiol Scandinavica 1926, 1(suppl):1-128.
3. Richards F.M., Crossey P.A., Phipps M.E., et al. Detailed mapping of germline deletions of the von Hippel-Lindau disease tumour suppressor gene. Hum Mol Genet 1994, 3(4):595-598.
4. Richards F.M., Maher E.R., Latif F., et al. Detailed genetic mapping of the von Hippel-Lindau disease tumour suppressor gene. J Med Genet 1993, 30(2):104-107.
5. Richards F.M., Phipps M.E., Latif F., et al. Mapping the Von Hippel-Lindau disease tumour suppressor gene: identification of germline deletions by pulsed field gel electrophoresis. Hum Mol Genet 1993, 2(7):879-882.
6. Latif F., Tory K., Gnarra J., et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993, 260(5112):1317-1320.
7. Maher E.R., Bentley E., Yates J.R., et al. Mapping of the von Hippel-Lindau disease locus to a small region of chromosome 3p by genetic linkage analysis. Genomics 1991, 10(4):957-960.
8. Maher E.R., Webster A.R., Richards F.M., et al. Phenotypic expression in von Hippel-Lindau disease: correlations with germline VHL gene mutations. J Med Genet 1996, 33(4):328-332.
9. Ong K.R., Woodward E.R., Killick P., Lim C., Macdonald F., Maher E.R. Genotype-phenotype correlations in von Hippel-Lindau disease. Hum Mutat 2007, 28(2):143-149.
10. Zbar B., Kishida T., Chen F., et al. Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum Mutat 1996, 8(4):348-357.
11. Hes F., Zewald R., Peeters T., et al. Genotype-phenotype correlations in families with deletions in the von Hippel-Lindau (VHL) gene. Hum Genet 2000, 106(4):425-431.
12. Chen F., Kishida T., Yao M., et al. Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Hum Mutat 1995, 5(1):66-75.
13. Brauch H., Kishida T., Glavac D., et al. Von Hippel-Lindau (VHL) disease with pheochromocytoma in the Black Forest region of Germany: evidence for a founder effect. Hum Genet 1995, 95(5):551-556.
14. Maher E.R., Iselius L., Yates J.R., et al. Von Hippel-Lindau disease: a genetic study. J Med Genet 1991, 28(7):443-447.
15. Maher E.R., Yates J.R., Harries R., et al. Clinical features and natural history of von Hippel-Lindau disease. Q J Med 1990, 77(283):1151-1163.
16. Crossey P.A., Foster K., Richards F.M., et al. Molecular genetic investigations of the mechanism of tumourigenesis in von Hippel-Lindau disease: analysis of allele loss in VHL tumours. Hum Genet 1994, 93(1):53-58.
17. Murgia A., Martella M., Vinanzi C., Polli R., Perilongo G., Opocher G. Somatic mosaicism in von Hippel-Lindau Disease. Hum Mutat 2000, 15(1):114.
18. Sgambati M.T., Stolle C., Choyke P.L., et al. Mosaicism in von Hippel-Lindau disease: lessons from kindreds with germline mutations identified in offspring with mosaic parents. Am J Hum Genet 2000, 66(1):84-91.
19. Vortmeyer A.O., Lubensky I.A., Fogt F., Linehan W.M., Khettry U., Zhuang Z. Allelic deletion and mutation of the von Hippel-Lindau (VHL) tumor suppressor gene in pancreatic microcystic adenomas. Am J Pathol 1997, 151(4):951-956.
20. Tse J.Y., Wong J.H., Lo K.W., Poon W.S., Huang D.P., Ng H.K. Molecular genetic analysis of the von Hippel-Lindau disease tumor suppressor gene in familial and sporadic cerebellar hemangioblastomas. Am J Clin Pathol 1997, 107(4):459-466.
21. Lubensky I.A., Gnarra J.R., Bertheau P., Walther M.M., Linehan W.M., Zhuang Z. Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients. Am J Pathol 1996, 149(6):2089-2094.
22. Mandriota S.J., Turner K.J., Davies D.R., et al. HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron. Cancer Cell 2002, 1(5):459-468.
23. Kibel A., Iliopoulos O., DeCaprio J.A., Kaelin W.G. Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science 1995, 269(5229):1444-1446.
24. Kishida T., Stackhouse T.M., Chen F., Lerman M.I., Zbar B. Cellular proteins that bind the von Hippel-Lindau disease gene product: mapping of binding domains and the effect of missense mutations. Cancer Res 1995, 55(20):4544-4548.
25. Stebbins C.E., Kaelin W.G., Pavletich N.P. Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. Science 1999, 284(5413):455-461.
26. Ohh M., Takagi Y., Aso T., et al. Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau protein. J Clin Invest 1999, 104(11):1583-1591.
27. Cockman M.E., Masson N., Mole D.R., et al. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumorsuppressor protein. J Biol Chem 2000, 275(33):25733-25741.
28. Kim W., Kaelin W.G. The von Hippel-Lindau tumor suppressor protein: new insights into oxygen sensing and cancer. Curr Opin Genet Dev 2003, 13(1):55-60.
29. Banks R.E., Tirukonda P., Taylor C., et al. Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res 2006, 66(4):2000-2011.
30. Dondeti V.R., Wubbenhorst B., Lal P., et al. Integrative genomic analyses of sporadic clear cell renal cell carcinoma define disease subtypes and potential new therapeutic targets. Cancer Res 2012, 72(1):112-121.
31. Gordan J.D., Lal P., Dondeti V.R., et al. HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 2008, 14(6):435-446.
32. Richards F.M., Webster A.R., McMahon R., Woodward E.R., Rose S., Maher E.R. Molecular genetic analysis of von Hippel-Lindau disease. J Intern Med 1998, 243(6):527-533.
33. Li L., Zhang L., Zhang X., et al. Hypoxia-inducible factor linked to differential kidney cancer risk seen with type 2A and type 2B VHL mutations. Mol Cell Biol 2007, 27(15):5381-5392.
34. Clifford S.C., Cockman M.E., Smallwood A.C., et al. Contrasting effects on HIF-1alpha regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in von Hippel-Lindau disease. Hum Mol Genet 2001, 10(10):1029-1038.
35. Knauth K., Bex C., Jemth P., Buchberger A. Renal cell carcinoma risk in type 2 von Hippel-Lindau disease correlates with defects in pVHL stability and HIF-1alpha interactions. Oncogene 2006, 25(3):370-377.
36. Goldfarb D.A., Neumann H.P., Penn I., Novick A.C. Results of renal transplantation in patients with renal cell carcinoma and von Hippel-Lindau disease. Transplantation 1997, 64(12):1726-1729.
37. Walther M.M., Choyke P.L., Glenn G., et al. Renal cancer in families with hereditary renal cancer: prospective analysis of a tumor size threshold for renal parenchymal sparing surgery. J Urol 1999, 161(5):1475-1479.
38. Duffey B.G., Choyke P.L., Glenn G., et al. The relationship between renal tumor size and metastases in patients with von Hippel-Lindau disease. J Urol 2004, 172(1):63-65.
39. Choueiri T.K., Plantade A., Elson P., et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol 2008, 26(1):127-131.
40. Rahma O.E., Ashtar E., Ibrahim R., et al. A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic renal cell carcinoma. J Transl Med 2010, 8:8.
41. Alleman W.G., Tabios R.L., Chandramouli G.V., et al. The invitro andinvivo effects of re-expressing methylated von Hippel-Lindau tumor suppressor gene in clear cell renal carcinoma with5-aza-2'-deoxycytidine. Clin Cancer Res 2004, 10(20):7011-7021.
42. Zbar B., Glenn G., Lubensky I., et al. Hereditary papillary renal cell carcinoma: clinical studies in 10 families. J Urol 1995, 153(3 Pt 2):907-912.
43. Zbar B., Tory K., Merino M., et al. Hereditary papillary renal cell carcinoma. J Urol 1994, 151(3):561-566.
44. Schmidt L., Duh F.M., Chen F., et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997, 16(1):68-73.
45. Schmidt L., Junker K., Nakaigawa N., et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 1999, 18(14):2343-2350.
46. Lubensky I.A., Schmidt L., Zhuang Z., et al. Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. Am J Pathol 1999, 155(2):517-526.
47. Lindor N.M., Dechet C.B., Greene M.H., et al. Papillary renal cell carcinoma: analysis of germline mutations in the MET proto-oncogene in a clinic-based population. Genet Test 2001, 5(2):101-106.
48. Dharmawardana P.G., Giubellino A., Bottaro D.P. Hereditary papillary renal carcinoma type I. Curr Mol Med 2004, 4(8):855-868.
49. Toro J.R., Nickerson M.L., Wei M.H., et al. Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am J Hum Genet 2003, 73(1):95-106.
50. Alam N.A., Rowan A.J., Wortham N.C., et al. Genetic and functional analyses of FH mutations in multiple cutaneous and uterine leiomyomatosis, hereditary leiomyomatosis and renal cancer, and fumarate hydratase deficiency. Hum Mol Genet 2003, 12(11):1241-1252.
51. Merino M.J., Torres-Cabala C., Pinto P., Linehan W.M. The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome. Am J Surg Pathol 2007, 31(10):1578-1585.
52. Grubb R.L., Franks M.E., Toro J., et al. Hereditary leiomyomatosis and renal cell cancer: a syndrome associated with an aggressive form of inherited renal cancer. J Urol 2007, 177(6):2074-2079. discussion 2079-80.
53. Wei M.H., Toure O., Glenn G.M., et al. Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer. J Med Genet 2006, 43(1):18-27.
54. Smit D.L., Mensenkamp A.R., Badeloe S., et al. Hereditary leiomyomatosis and renal cell cancer in families referred for fumarate hydratase germline mutation analysis. Clin Genet 2011, 79(1):49-59.
55. Bayley J.P., Launonen V., Tomlinson I.P. The FH mutation database: an online database of fumarate hydratase mutations involved in the MCUL (HLRCC) tumor syndrome and congenital fumarase deficiency. BMC Med Genet 2008, 9:20.
56. Pithukpakorn M., Wei M.H., Toure O., et al. Fumarate hydratase enzyme activity in lymphoblastoid cells and fibroblasts of individuals in families with hereditary leiomyomatosis and renal cell cancer. J Med Genet 2006, 43(9):755-762.
57. Gardie B., Remenieras A., Kattygnarath D., et al. Novel FH mutations in families with hereditary leiomyomatosis and renal cell cancer (HLRCC) and patients with isolated type 2 papillary renal cell carcinoma. J Med Genet 2011, 48(4):226-234.
58. Vahteristo P., Koski T.A., Naatsaari L., et al. No evidence for a genetic modifier for renal cell cancer risk in HLRCC syndrome. Fam Cancer 2010, 9(2):245-251.
59. Gellera C., Uziel G., Rimoldi M., et al. Fumarase deficiency is an autosomal recessive encephalopathy affecting both the mitochondrial and the cytosolic enzymes. Neurology 1990, 40(3 Pt 1):495-499.
60. Bourgeron T., Chretien D., Poggi-Bach J., et al. Mutation of the fumarase gene in two siblings with progressive encephalopathy and fumarase deficiency. J Clin Invest 1994, 93(6):2514-2518.
61. Coughlin E.M., Christensen E., Kunz P.L., et al. Molecular analysis and prenatal diagnosis of human fumarase deficiency. Mol Genet Metab 1998, 63(4):254-262.
62. Bonioli E., Di Stefano A., Peri V., et al. Fumarate hydratase deficiency. J Inherit Metab Dis 1998, 21(4):435-436.
63. Maradin M., Fumic K., Hansikova H., et al. Fumaric aciduria: mild phenotype in a 8-year-old girl with novel mutations. J Inherit Metab Dis 2006, 29(5):683.
64. Ottolenghi C., Hubert L., Allanore Y., et al. Clinical and biochemical heterogeneity associated with fumarase deficiency. Hum Mutat 2011, 32(9):1046-1052.
65. Linehan W.M., Rouault T.A. Molecular pathways: fumarate hydratase-deficient kidney cancer-targeting the warburg effect in cancer. Clin Cancer Res 2013, 19(13):3345-3352.
66. Adam J., Hatipoglu E., O'Flaherty L., et al. Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling. Cancer Cell 2011, 20(4):524-537.
67. Ooi A., Wong J.C., Petillo D., et al. An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma. Cancer Cell 2011, 20(4):511-523.
68. Giudice A., Arra C., Turco M.C. Review of molecular mechanisms involved in the activation of the Nrf2-ARE signaling pathway by chemopreventive agents. Methods Mol Biol 2010, 647:37-74.
69. Tong W.H., Sourbier C., Kovtunovych G., et al. The glycolytic shift in fumarate-hydratase-deficient kidney cancer lowers AMPK levels, increases anabolic propensities and lowers cellular iron levels. Cancer Cell 2011, 20(3):315-327.
70. Bardella C., El-Bahrawy M., Frizzell N., et al. Aberrant succination of proteins in fumarate hydratase-deficient mice and HLRCC patients is a robust biomarker of mutation status. J Pathol 2011, 225(1):4-11.
71. Maxwell P.H. Seeing the smoking gun: a sensitive and specific method to visualize loss of the tumour suppressor, fumarate hydratase, in human tissues. J Pathol 2011, 225(1):1-3.
72. Koski T.A., Lehtonen H.J., Jee K.J., et al. Array comparative genomic hybridization identifies a distinct DNA copy number profile in renal cell cancer associated with hereditary leiomyomatosis and renal cell cancer. Genes Chromosomes Cancer 2009, 48(7):544-551.
73. Launonen V., Vierimaa O., Kiuru M., et al. Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc Natl Acad Sci U S A 2001, 98(6):3387-3392.
74. Tomlinson I.P., Alam N.A., Rowan A.J., et al. Germline mutations inFH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 2002, 30(4):406-410.
75. Stewart L., Glenn G.M., Stratton P., et al. Association of germline mutations in the fumarate hydratase gene and uterine fibroids in women with hereditary leiomyomatosis and renal cell cancer. Arch Dermatol 2008, 144(12):1584-1592.
76. Garg K., Tickoo S.K., Soslow R.A., Reuter V.E. Morphologic features of uterine leiomyomas associated with hereditary leiomyomatosis and renal cell carcinoma syndrome: a case report. Am J Surg Pathol 2011, 35(8):1235-1237.
77. Alam N.A., Barclay E., Rowan A.J., et al. Clinical features of multiple cutaneous and uterine leiomyomatosis: an underdiagnosed tumor syndrome. Arch Dermatol 2005, 141(2):199-206.
78. Badeloe S., van Spaendonck-Zwarts K.Y., van Steensel M.A., et al. Wilms tumour as a possible early manifestation of hereditary leiomyomatosis and renal cell cancer?. Br J Dermatol 2009, 160(3):707-709.
79. Carvajal-Carmona L.G., Alam N.A., Pollard P.J., et al. Adult Leydig cell tumors of the testis caused by germline fumarate hydratase mutations. J Clin Endocrinol Metab 2006, 91(8):3071-3075.
80. Lamba M., Verma S., Prokopetz R., Pierscianowski T.A., Jabi M., Moyana T. Multiple cutaneous and uterine leiomyomas associated with gastric GIST. J Cutan Med Surg 2005, 9(6):332-335.
81. Matyakhina L., Freedman R.J., Bourdeau I., et al. Hereditary leiomyomatosis associated with bilateral, massive, macronodular adrenocortical disease and atypical Cushing syndrome: a clinical and molecular genetic investigation. J Clin Endocrinol Metab 2005, 90(6):3773-3779.
82. Eder J.P., Shapiro G.I., Appleman L.J., et al. A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2. Clin Cancer Res 2010, 16(13):3507-3516.
83. Choueiri T.K., Vaishampayan U., Rosenberg J.E., et al. Phase II andbiomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol 2013, 31(2):181-186.
84. Gordon M.S., Hussey M., Nagle R.B., et al. Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317. J Clin Oncol 2009, 27(34):5788-5793.
85. Khoo S.K., Bradley M., Wong F.K., Hedblad M.A., Nordenskjold M., Teh B.T. Birt-Hogg-Dube syndrome: mapping of a novel hereditary neoplasia gene to chromosome 17p12-q11.2. Oncogene 2001, 20(37):5239-5242.
86. Schmidt L.S., Warren M.B., Nickerson M.L., et al. Birt-Hogg-Dube syndrome, a genodermatosis associated with spontaneous pneumothorax and kidney neoplasia, maps to chromosome 17p11.2. Am J Hum Genet 2001, 69(4):876-882.
87. Nickerson M.L., Warren M.B., Toro J.R., et al. Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dube syndrome. Cancer Cell 2002, 2(2):157-164.
88. Benhammou J.N., Vocke C.D., Santani A., et al. Identification of intragenic deletions and duplication in the FLCN gene in Birt-Hogg-Dube syndrome. Genes Chromosomes Cancer 2011, 50(6):466-477.
89. Luijten M.N., Basten S.G., Claessens T., et al. Birt-Hogg-Dube syndrome is a novel ciliopathy. Hum Mol Genet 2013, 22(21):4383-4397.
90. Medvetz D.A., Khabibullin D., Hariharan V., et al. Folliculin, the product of the Birt-Hogg-Dube tumor suppressor gene, interacts with the adherens junction protein p0071 to regulate cell-cell adhesion. PLoS One 2012, 7(11):e47842.
91. Gaur K., Li J., Wang D., et al. The Birt-Hogg-Dube tumor suppressor Folliculin negatively regulates ribosomal RNA synthesis. Hum Mol Genet 2013, 22(2):284-299.
92. Pavlovich C.P., Grubb R.L., Hurley K., et al. Evaluation and management of renal tumors in the Birt-Hogg-Dube syndrome. J Urol 2005, 173(5):1482-1486.
93. Khoo S.K., Kahnoski K., Sugimura J., et al. Inactivation of BHD in sporadic renal tumors. Cancer Res 2003, 63(15):4583-4587.
94. da Silva N.F., Gentle D., Hesson L.B., Morton D.G., Latif F., Maher E.R. Analysis of the Birt-Hogg-Dube (BHD) tumour suppressor gene in sporadic renal cell carcinoma and colorectal cancer. J Med Genet 2003, 40(11):820-824.
95. Menko F.H., van Steensel M.A., Giraud S., et al. Birt-Hogg-Dube syndrome: diagnosis and management. Lancet Oncol 2009, 10(12):1199-1206.
96. Linehan W.M., Pinto P.A., Bratslavsky G., et al. Hereditary kidney cancer: unique opportunity for disease-based therapy. Cancer 2009, 115(suppl 10):2252-2261.
97. Pena-Llopis S., Vega-Rubin-de-Celis S., Liao A., et al. BAP1 loss defines a new class of renal cell carcinoma. Nat Genet 2012, 44(7):751-759.
98. Kapur P., Pena-Llopis S., Christie A., et al. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. Lancet Oncol 2013, 14(2):159-167.
99. Farley M.N., Schmidt L.S., Mester J.L., et al. A novel germline mutation in BAP1 predisposes to familial clear-cell renal cell carcinoma. Mol Cancer Res 2013, 11(9):1061-1071.
100. Popova T., Hebert L., Jacquemin V., et al. Germline BAP1 mutations predispose to renal cell carcinomas. Am J Hum Genet 2013, doi:10.1016/j.ajhg.2013.04.012.
101. Bodmer D., Eleveld M., Ligtenberg M., et al. Cytogenetic and molecular analysis of early stage renal cell carcinomas in a family with a translocation (2;3) (q35;q21). Cancer Genet Cytogenet 2002, 134(1):6-12.
102. Bonne A.C., Bodmer D., Schoenmakers E.F., van Ravenswaaij C.M., Hoogerbrugge N., van Kessel A.G. Chromosome 3 translocations and familial renal cell cancer. Curr Mol Med 2004, 4(8):849-854.
103. Eleveld M.J., Bodmer D., Merkx G., et al. Molecular analysis of a familial case of renal cell cancer and a t(3;6) (q12;q15). Genes Chromosomes Cancer 2001, 31(1):23-32.
104. Foster R.E., Abdulrahman M., Morris M.R., et al. Characterization of a 3;6 translocation associated with renal cell carcinoma. Genes Chromosomes Cancer 2007, 46(4):311-317.
105. Kanayama H., Lui W.O., Takahashi M., et al. Association of a novel constitutional translocation t(1q;3q) with familial renal cell carcinoma. J Med Genet 2001, 38(3):165-170.
106. Koolen M.I., van der Meyden A.P., Bodmer D., et al. A familial case of renal cell carcinoma and a t(2;3) chromosome translocation. Kidney Int 1998, 53(2):273-275.
107. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013, 499(7456):43-49.
108. Liaw D., Marsh D.J., Li J., et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 1997, 16(1):64-67.
109. Gustafson S., Zbuk K.M., Scacheri C., Eng C. Cowden syndrome. Semin Oncol 2007, 34(5):428-434.
110. Zbuk K.M., Eng C. Cancer phenomics: RET and PTEN as illustrative models. Nat Rev Cancer 2007, 7(1):35-45.
111. Lynch E.D., Ostermeyer E.A., Lee M.K., et al. Inherited mutations in PTEN that are associated with breast cancer, Cowden disease, and juvenile polyposis. Am J Hum Genet 1997, 61(6):1254-1260.
112. Tan M.H., Mester J.L., Ngeow J., Rybicki L.A., Orloff M.S., Eng C. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res 2012, 18(2):400-407.
113. Kondo K., Yao M., Kobayashi K., et al. PTEN/MMAC1/TEP1 mutations in human primary renal-cell carcinomas and renal carcinoma cell lines. Int J Cancer 2001, 91(2):219-224.
114. Letouze E., Martinelli C., Loriot C., et al. SDH mutations establish a hypermethylator phenotype in paraganglioma. Cancer Cell 2013, 23(6):739-752.
115. Astuti D., Latif F., Dallol A., et al. Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet 2001, 69(1):49-54.
116. Amar L., Baudin E., Burnichon N., et al. Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas. J Clin Endocrinol Metab 2007, 92(10):3822-3828.
117. Ricketts C., Woodward E.R., Killick P., et al. Germline SDHB mutations and familial renal cell carcinoma. J Nat Cancer Inst 2008, 100(17):1260-1262.
118. Vanharanta S., Buchta M., McWhinney S.R., et al. Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma. Am J Hum Genet 2004, 74(1):153-159.
119. Morris M.R., Maina E., Morgan N.V., et al. Molecular genetic analysis of FIH-1, FH, and SDHB candidate tumour suppressor genes in renal cell carcinoma. J Clin Pathol 2004, 57(7):706-711.
120. Ricketts C.J., Shuch B., Vocke C.D., et al. Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer. J Urol 2012, 188(6):2063-2071.
121. Crino P.B., Nathanson K.L., Henske E.P. The tuberous sclerosis complex. N Engl J Med 2006, 355(13):1345-1356.
122. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 1993, 75(7):1305-1315. European Chromosome 16 Tuberous Sclerosis Consortium.
123. Kozlowski P., Roberts P., Dabora S., et al. Identification of 54 large deletions/duplications in TSC1 and TSC2 using MLPA, and genotype-phenotype correlations. Hum Genet 2007, 121(3-4):389-400.
124. van Slegtenhorst M., de Hoogt R., Hermans C., et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 1997, 277(5327):805-808.
125. Dabora S.L., Jozwiak S., Franz D.N., et al. Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs. Am J Hum Genet 2001, 68(1):64-80.
126. Dixon B.P., Hulbert J.C., Bissler J.J. Tuberous sclerosis complex renal disease. Nephron Exp Nephrol 2011, 118(1):e15-e20.
127. Bissler J.J., Kingswood J.C., Radzikowska E., et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex orsporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2013, 381(9869):817-824.